| Document |
Document Title |
|
WO/2015/095340A1 |
This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipi...
|
|
WO/2015/088893A1 |
A corrosion-inhibiting composition includes a diluent and a mixture of organic salts of half ester-half acids of a dioic acid with of a glyceride group with a fatty acyl residue. Included are organic salts of glyceride-cyclic carboxylic ...
|
|
WO/2015/080183A1 |
A compound represented by general formula (1) is useful as a light-emitting material. In general formula (1), zero to one of R1 to R5 represents a cyano group, one to five of R1 to R5 independently represent a group represented by genera...
|
|
WO/2015/067450A1 |
The invention relates to a method for producing amines, comprising the following steps: a. reacting a (i) carboxylic acid amide of general formula (I) or (ii) carboxylic acid diamide of general formula (II) or (iii) di-, tri-, or polypep...
|
|
WO/2015/068770A1 |
A method for producing carboxylic acid amide that obtains carboxylic acid amide by dehydrocondensation of carboxylic acid and amine, wherein arylboronic acid having an electron-attracting group at the meta position and/or para position i...
|
|
WO/2015/055447A1 |
The present invention relates to a process for preparing substituted isatoic acid anhydride compounds of the formula (I) in which R1 is Cl, Br, I, or CN; and R2 is CH3, Cl, Br; using anthranilic acid derivative compounds of formula (III)...
|
|
WO/2015/042685A1 |
Compounds which inhibit the formation and/or accumulation of RNA foci, such as those due to polynucleotide repeats (e.g., trinucleotide repeats) are described herein. Also described herein are uses of such compounds, such as for the inhi...
|
|
WO/2015/042397A1 |
Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associat...
|
|
WO/2015/034820A1 |
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowin...
|
|
WO/2015/028409A1 |
The invention relates to selective estrogen receptor modulators (SERMs) and to methods for the preparation thereof, to the use thereof for the treatment and/or prophylaxis of disorders, and to the use thereof for producing medicaments fo...
|
|
WO/2015/029354A1 |
[Problem] To provide a compound which emits fluorescence and delayed fluorescence as a material for a high efficiency organic electroluminescent element, and to further provide an organic photoluminescent element and a high efficiency, h...
|
|
WO/2015/027058A2 |
Cycloalkyl amine compounds of Formula (I), wherein ring A is C3-C6 cycloalkyl, optionally substituted with one or more C1-C3 alkyl, and R5 is ORS2, in which RS2 is H or C1-C6 alkyl, or R5 and R6, together with the carbon atom to which th...
|
|
WO/2015/025717A1 |
The objective of the present invention is to provide: a photoelectric conversion element which has excellent responsivity and high photoelectric conversion efficiency, and which can be produced by vapor deposition; and an optical sensor ...
|
|
WO/2015/020553A1 |
The present invention provides carbazole compounds of the formula (I), which can be used for treating microbial, protozoan, viral infections and cancer. 
|
|
WO/2015/010626A1 |
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.
|
|
WO/2015/012332A1 |
The present invention provides a therapeutic agent or a preventive agent for ophthalmic diseases caused by ocular neovascularization, the agent comprising as an active ingredient a morpholine compound represented by general formula (1) (...
|
|
WO/2015/007630A1 |
The present invention relates to new salts, complexes, crystals, solutions, dispersions, and slurries of threonine-N,N-diacetic acid or derivatives thereof, to formulations containing those, to processes to prepare those, and to the use ...
|
|
WO/2014/202589A1 |
The present invention relates to a process for manufacturing 4-propargylated amino- benzoxazinones of formula (I), comprising the following steps: step a) preparing propargyl chloride by reacting propargyl alcohol with thionyl chloride o...
|
|
WO/2014/203840A1 |
A compound represented by general formula (1) is a red light-emitting material that has a high luminous efficiency. R1 to R8 each represent a hydrogen atom or a substituent group, at least one from among R1 to R8 being a group represente...
|
|
WO/2014/200880A1 |
The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates t...
|
|
WO/2014/193337A1 |
Disclosed are antioxidative, natural compounds, their salts, chelates and cleavage derivatives that exhibit a superior combination of properties. The compounds can be used for a variety of purposes, including stabilizing foods, cosmetics...
|
|
WO/2014/193338A1 |
Disclosed are antioxidative natural compounds, their salts, chelates and cleavage derivatives that exhibit a superior combination of properties. The compounds can be used for a variety of purposes, including the stabilization of polymers...
|
|
WO/2014/174745A1 |
Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water-soluble polycyclic compound or a pharmacologically acceptable salt thereof has a greater solubility in an aqueous solvent and has Eg5 inhibitory activity ...
|
|
WO/2014/175563A1 |
The present invention provides a method of preparing 4-(4-aminophenyl)-3-morpholinone, including the step of reducing 4-(4-nitrophenyl)-3-morpholinone by reacting sodium hydrosulfite (Na2S2O4) with 4-(4-nitrophenyl)-3-morpholinone. This ...
|
|
WO/2014/168101A1 |
A compound represented by general formula (1) is useful as a luminescent material. R1-R10 represent hydrogen atoms or substituents, but at least one of R1-R10 is a group represented by general formula (2). R21-R30 represent hydrogen atom...
|
|
WO/2014/159809A1 |
The present invention relates in part to a method of stabilizing chloropropenes, such as 1,1,2,3-tetrachloropropene, otherwise known to decompose and degrade, and to the resulting stabilized chloropropene, using a morpholine compound and...
|
|
WO/2014/146752A1 |
The present application relates to a compound of a formula (I) which comprises a benzene group that is substituted with a group selected from carbazole derivatives and bridged amines and with an electron attracting group, wherein the two...
|
|
WO/2014/142255A1 |
Provided is a heterocyclic compound exhibiting an RORγt-inhibiting action. Specifically provided is a compound represented by formula (I) or a salt thereof. [In the formula, Ar indicates partial formulas (1) through (5), Q indicates a b...
|
|
WO/2014/145118A1 |
Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative di...
|
|
WO/2014/142320A1 |
Provided is a compound represented by general formula (I) and capable of detecting lipid droplets and/or adipose tissue. (In formula (I), R1 represents a C1-4 alkyl group, R2 represents a C1-4 alkyl group, and X is a group represented by...
|
|
WO/2014/138484A1 |
PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase ...
|
|
WO/2014/137717A1 |
The present disclosure provides a curable composition containing a benzoxazine and a polysulfone-based toughener. The curable composition, upon curing, renders a cured article having well balanced thermal, chemical and mechanical propert...
|
|
WO/2014/134341A1 |
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formu...
|
|
WO/2014/130470A1 |
The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the tre...
|
|
WO/2014/125410A1 |
The present invention provides N-substituted novel heterocyclic derivatives of formula (I) as protein kinase inhibitors, in which R1, R2 and 'n' have the same meanings given in the specification, and pharmaceutically acceptable salts the...
|
|
WO/2014/115692A1 |
The purpose of the present invention is to provide a phthalocyanine compound which exhibits excellent light resistance and heat resistance and which is useful as a near-infrared absorbing agent. It was discovered that a phthalocyanine co...
|
|
WO/2014/113467A1 |
Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer...
|
|
WO/2014/110491A1 |
Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable...
|
|
WO/2014/107622A1 |
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
|
|
WO/2014/096407A1 |
The present invention relates to test devices for determining the presence of one or more analytes in a sample, methods for using such test devices and methods of manufacturing such test devices. The test devices comprise a substrate hav...
|
|
WO/2014/097188A1 |
The present invention concerns new compounds of 2,3-dihydro-4H-1,3- benzoxazine-4-one, a method for preparing the said compounds, a pharmaceutical form that contains the said compounds, and their use. In particular, the present invention...
|
|
WO/2014/096377A1 |
New hydroxy aliphatic substituted phenyl aminoalkyi ether compounds of formula (I), compositions thereof and their use as a medicament in the treatment of nervous system diseases and/or the treatment of developmental, behavioral and/or m...
|
|
WO/2014/081024A1 |
The present invention provides a novel method for the preparation of a compound represented by formula (I) [wherein R1, R2, R3, R4 and X have the same meanings as those defined in the claims with respect to R1, R2, R3, R4 and X], a pharm...
|
|
WO/2014/081025A1 |
This invention relates to an I-form crystal of the free form of 3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyetho
xy)-5-(3-oxo-[1,2]-oxazinan-2-ylmethyl)benzamide, the crystal, in analysis by X-ray powder diffraction with CuKÎ...
|
|
WO/2014/076038A1 |
The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medica...
|
|
WO/2014/056958A1 |
The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to metho...
|
|
WO/2014/048547A1 |
The present invention relates to alpha hydroxy amides including compounds of formula (I) and related compounds and their use in the prophylaxis and treatment of inflammatory disorders and diseases, wherein T1, T2, W and Rw has the meanin...
|
|
WO/2014/046244A1 |
Provided are a novel production method and production intermediate for an herbicide. Provided are the following: with respect to a trifluoromethanesulfonanilide-type herbicide represented by formula (2): [in the formula, A denotes -CH=CH...
|
|
WO/2014/043019A1 |
The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are use...
|
|
WO/2014/042263A1 |
The invention provides a nitrogen-containing saturated heterocyclic compound useful as a renin inhibitor. A compound represented by formula [I] (in the formula, R1 represents a cycloalkyl or alkyl, R22 represents an optionally substitute...
|
